InvestorsHub Logo
Followers 41
Posts 6496
Boards Moderated 0
Alias Born 11/16/2003

Re: Tlsmd post# 6766

Sunday, 05/14/2017 4:23:13 PM

Sunday, May 14, 2017 4:23:13 PM

Post# of 7054
tried googling but couldn't come up with anything specific.Will look forward to any update you can provide.I think the next catalyst for FCSC is Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB),in the next quarter.

From the recent 5/8 news release:
As specified in the protocol of this Phase 1/2 trial, additional adult patients can begin to be dosed with this recommendation from the DSMB. Six adult patients are targeted for the Phase 1 portion of the trial. Twelve-week post-treatment data for safety, mechanism of action and efficacy for multiple patients in the Phase 1 portion of this trial are expected in the third quarter of 2017.